RGD peptide-conjugated polydopamine nanoparticles loaded with doxorubicin for combined chemotherapy and photothermal therapy in thyroid cancer Authors: Donglan Yuan, Zhiqiang Lu, Xindan Xu, Wei Liu Published: 2024 ABSTRACT AbstractObjectiveTo construct polydopamine (PDA)-based nanoparticles (NPs) for combined chemotherapy (CT) and photothermal therapy (PTT) of thyroid tumors by conjugating doxorubicin (DOX) via Schiff base reaction and decorating with RGD peptide.MethodsPDA NPs were synthesized using dopamine hydrochloride (DA) as the raw material and reacted with DOX-PEG-NH2 to obtain PDA-DOX NPs. Subsequently, RGD peptide was coupled with PDA-DOX NPs for modification. Their size, charge, and shape were characterized using DLS and SEM. The assembly of DOX was verified by ultraviolet–visible spectroscopy (UV–Vis), and the release efficiency of DOX under different pH conditions was calculated. The antitumor effect of RGD@PDA-DOX was validated in KTC-1 cells and tumor-bearing nude mice.ResultsThe prepared RGD@PDA-DOX exhibited excellent dispersion, stability, and biocompatibility. PDA-DOX possessed superior photothermal conversion efficiency, capable of rapidly elevating the solution temperature within 5 min. In vitro studies revealed that the inhibitory rate of RGD@PDA-DOX combined with 808 nm laser on KTC-1 cells reached 92% (p < 0.05). In vivo experiments demonstrated that RGD@PDA-DOX exhibits no cytotoxicity. The modification with RGD peptides enables RGD@PDA-DOX to target tumor regions and accumulate over an extended period. Additionally, RGD@PDA-DOX, when combined with an 808 nm laser, significantly inhibits tumor growth.ConclusionRGD@PDA-DOX can effectively accumulate in tumor regions and demonstrates excellent anti-tumor efficacy. It may serve as a feasible approach for the effective treatment of thyroid tumors, providing further evidence and data for clinical translation.Keywords: Thyroid Cancer, RGD@PDA-DOX, Drug delivery, Photothermal therapy, Clinical transformation Introduction Among head and neck cancers, the incidence of thyroid cancer has been increasing annually, and it has become a common type of malignant tumor [1]. Currently, the main treatment methods for thyroid cancer include surgical resection, radioactive iodine therapy (RAI), and targeted drug chemotherapy. These methods can be used alone or in combination. DOX is primarily used clinically as a broad-spectrum anticancer drug, particularly demonstrating significant efficacy in the treatment of breast cancer, lymphoma, sarcoma, and certain types of leukemia. By intercalating into human DNA, DOX blocks tumor cell proliferation and induces apoptosis, thereby achieving the purpose of cancer treatment. However, the clinical application of DOX is also limited by its significant cardiotoxicity. Cardiotoxicity of DOX manifests as various types of arrhythmias, pericarditis and myocarditis, acute hypertension, congestive heart failure, and even death. This cardiotoxicity poses a serious constraint on the clinical use of DOX [2]. To reduce the cardiotoxicity of DOX and enhance its therapeutic efficacy, researchers have been exploring new drug delivery methods and formulations. For instance, the combination of DOX with human serum albumin to form DOX-HSA complexes can increase drug accumulation in tumor tissues, enhance drug stability, and reduce toxicity to the heart and other vital organs. Additionally, nanocarriers such as BSANP have been employed for the delivery of DOX, aiming to improve drug stability, solubility, and prolong drug circulation time in the body [3].Nevertheless, despite these technological advancements that have mitigated the side effects of DOX to a certain extent, they cannot completely eliminate its cardiotoxicity. In addition to the traditional three therapies, photothermal therapy and its combination therapies have been extensively studied in recent years [4]. Compared with traditional surgical and radiotherapy/chemotherapy techniques, PTT has the advantages of minimal trauma, high specificity, and reduced side effects [5]. Firstly, traditional diagnostic and therapeutic methods are insufficient, with significant trauma and toxic side effects, while PTT, as a locally specific treatment, shows promising results. PTT is a non-invasive or minimally invasive therapy that ensures early recovery of the affected area after surgery and meets patients' aesthetic needs for treatment [6]. The thermal effect generated by PTT not only kills tumor cells directly but also promotes the uptake of chemotherapeutic drugs by cells by improving cell metabolism and membrane permeability, thus facilitating the entry of chemotherapeutic drug molecules into tumor cells for further killing of residual tumor cells, which acts as an adjuvant chemotherapy [7]. However, photothermal therapy (PTT) faces several challenges, including poor permeability and significant side effects. Therefore, how to effectively combine PTT with other therapeutic approaches has been a major concern for researchers. Arg-Gly-Asp (RGD) peptides are a class of polypeptides containing the amino acid sequence of arginine, glycine, and aspartic acid, which have the ability to bind to tumor-related cell surface receptors. These receptors often include members of the integrin family, such as αvβ3 and αvβ5 subtypes. Tumor cells and neovascular cells usually express high levels of integrins, so RGD peptides can be designed to target these cell surface receptors for targeted tumor therapy. Specifically, RGD peptides promote endocytosis of tumor cells or induce tumor angiogenesis by binding to integrins, achieving targeted therapeutic effects on tumors [8]. In this study, a nano-carrier system was constructed using the Schiff base reaction between PDA and DOX-PEG-NH2, and its targeting ability was enhanced by modifying RGD peptides. The nano-carrier RGD@PDA-DOX exhibits excellent encapsulation performance, high photothermal conversion efficiency, good stability, and responsive release. Cell experiments using thyroid cancer cell lines demonstrated that RGD@PDA-DOX can be delivered within cells, induce tumor cell death, and inhibit tumor cell proliferation. In vivo experiments showed that this nano-delivery platform has good biosafety, tumor targeting, and therapeutic effects. This provides new ideas and methods for the clinical treatment of thyroid cancer, and it has important developmental value. Materials and methods Materials Dopamine hydrochloride, doxorubicin (DOX), and coumarin-6 were purchased from Sigma-Aldrich (St. Louis, MO, USA). COOH-PEG-DOX and RGD peptide were obtained from Nanjing Peptide Biotech Co., Ltd. All chemicals used in cell experiments were purchased from KeyGEN BioTECH (Nanjing, China). Cell culture The human thyroid cancer cells (KTC-1) were purchased from Wuhan vector science Co.,Ltd (Dong Hu new technology development zone, Wuhan, Hubei, China). Dulbecco Modified Eagle’s Medium (DMEM; Hyclone, South Logan, UT, USA) was employed to culture KTC-1 cells at 37 °C in a humidified atmosphere of 5% CO2. All the mediums were contained with 10% fetal bovine serum (FBS; Hyclone, South Logan, UT, USA) and and 50 U/ml of penicillin/streptomycin. Synthesis of RGD@PDA-DOX Synthesis of PDA According to previous methods [9], DA (2 mg) was mixed in Tris–HCl (10 ml, 10 mM, pH 8.5) and stirred at room temperature for 8 h using a magnetic stirrer (500 rpm). Subsequently, the mixture was centrifuged at 12,000 rpm for 20 min, washed several times with deionized water, and then centrifuged again at 12,000 rpm for 20 min to remove the supernatant and collect the PDA NPs. Synthesis of PDA-DOX DOX-PEG-NH2 (3 mg) and PDA NPs (10 mg) were dissolved in water and vigorously stirred at room temperature. The mixture was then emulsified by ultrasound (20 kHz) for 10 min. Afterward, the mixture was centrifuged at 14,000 rpm for 20 min at room temperature, washed three times with water, and centrifuged again at 14,000 rpm for 20 min at room temperature to remove the supernatant and collect the PDA-DOX NPs. Preparation of RGD@PDA-DOX RGD peptide (3 mg) and PDA-DOX NPs (10 mg) were mixed with water and vigorously stirred at 26 °C to obtain an RGD@PDA-DOX suspension. Further analysis and characterization were then performed. Characterization of RGD@PDA-DOX The morphology and particle size of RGD@PDA-DOX were analyzed by scanning electron microscopy (SEM, JEOL, Japan). The zeta potential and Polymer dispersity index (PDI) of PDA NPs and RGD@PDA-DOX was measured by dynamic light scattering (DLS, Malvern Instruments, UK). The spectra of DOX and PDA-DOX were measured using a UV–Vis spectrophotometer (Shanghai Mapada Instruments Co., Ltd., China), and the sustained release efficiency of DOX under different pH conditions was calculated. Photothermal conversion efficiency of RGD@PDA-DOX RGD@PDA-DOX was diluted into four concentrations using phosphate buffer solution (PBS), and the heat generation efficiency under 808 nm irradiation was measured for each concentration. In vitro inhibition of tumor proliferation by RGD@PDA-DOX KTC-1 cells were seeded in 96-well plates at a density of 1 × 104 cells per well and incubated with PDA NPs, PDA-DOX NPs, and RGD@PDA-DOX NPs for 24 h. Subsequently, the experimental groups were irradiated with 808 nm laser (1 W/cm2) for 10 min. Cell viability was then assessed using CCK-8 after 6 h of incubation, and the optical density values were measured using a microplate reader (Thermo Scientific, China). Cellular internalization Coumarin-6 (C6), a lipophilic laser dye with green fluorescence that primarily binds to cell membranes, was mixed with RGD@PDA-DOX to visualize cellular internalization. Cultured cells were digested with trypsin, dispersed in complete medium, and seeded in confocal dishes at a concentration of 1 × 104/mL. After incubation in a 37 °C incubator with 5% CO2 until the cells reached approximately 40% confluence and no aggregation was observed, the NPs were added to the cells and further incubated. At 2 h, 4 h, 6 h, and 8 h, the cells were fixed with 4% paraformaldehyde for 10 min, nuclei were labeled with DAPI, and the internalization of NPs was observed using a confocal laser scanning microscope (Zeiss, Germany). The fluorescence intensity was quantitatively analyzed using ImageJ. Animal model A total of 20 tumor-bearing mice reared under SPF conditions were randomly divided into four groups. A single-cell suspension of luciferase-labeled TPC-1 cells was prepared in PBS (1 × 10⁷ cells/mL). A volume of 0.2 mL of the cell suspension was injected subcutaneously into the right axillary region of the mice to establish a thyroid tumor model. Treatment was initiated when the tumors reached 50 mm3. Once the model was successfully established, 10 µL of PBS, DOX, RGD@PDA, and RGD@PDA-DOX were injected, respectively. After 24 h, one mouse from each group was randomly selected and sacrificed. The accumulation of the injected materials in the mice’s organs (hearts, livers, spleens, lungs, kidneys) and tumor regions was observed using an IVIS Lumina imaging system (PerkinElmer, USA). The light-exposed groups were irradiated with 808 nm laser (1 w/cm2) for 5 min at a distance of 15 cm. Tumor volume was photographed and measured 24 h after irradiation using an IVIS Lumina imaging system (Perkin Elmer, America), and treatments were administered once every 7 days for a total of two weeks. Mouse body weight and tumor size were recorded every 2 days during the treatment period. On day 14, the mice were euthanized by an injection of sodium pentobarbital, and tumor tissues were excised, measured, weighed, and photographed [10]. H&E staining After the acute toxicity experiment, mice were sacrificed, and the corresponding tissues were extracted and preserved in formalin. The specific region of the tissue to be sliced was roughly separated, and the tissue was dehydrated using a series of reagents to enable infiltration and penetration of paraffin. The tissue was then sliced using a paraffin slicing machine and attached to a slide. The slide was heated in an oven or on a hot plate to assist in adhering the tissue to the slide. Prior to staining, the wax on the slide was removed using a solvent. Hematoxylin was preheated to 50 °C, and the staining was performed for 5 min. The slide was placed in a 50 °C incubator, washed with water for 1 min to remove excess dye, and then allowed to dry. It was then differentiated using 1% hydrochloric acid in alcohol for several seconds, rinsed with tap water, counterstained with 0.6% ammonia for 5 min, followed by rinsing with running water and drying. Subsequently, the slices were immersed in eosin staining solution for 1–3 min, rinsed with water for 1 min, dried, and finally dehydrated and mounted. Data analysis All experimental results were expressed as mean ± standard deviation and statistically analyzed using GraphPad Prism software. Results were analyzed by two-tailed Student’s t-test for two groups and one-way ANOVA for multiple groups. *p < 0.05, **p < 0.01 and ***p < 0.001 were considered to be statistically significant. Results Characterization of RGD@PDA-DOX Excellent stability is conducive to long-term storage of nanocarrier particles. As shown in Fig. 1A, SEM images revealed good dispersibility and uniform particle size of RGD@PDA-DOX. PDA, PDA-DOX, RGD@PDA-DOX The particle size results are shown in Table 1, where both DOX and RGD modified nanoparticles showed an increase in particle size. Using ImageJ to extract and measure the particles in the image, the average particle size of RGD@PDA-DOX was calculated to be approximately 102 nm. Larger particles observed in the image could be attributed to PDA agglomeration. Additionally, we measured the particle size and dispersity (Fig. 1B and C), both indicating good uniformity of the prepared particles. As shown in Fig. 1D, the characteristic absorption peak of C = O disappeared, while strong characteristic absorption peaks appeared around 1600 cm−1, indicating the formation of new C = N double bonds. This confirms the successful occurrence of the Schiff base reaction. Further measurements of the UV spectra of DOX and PDA-DOX were conducted. As shown in Fig. 1E, PDA-DOX exhibited distinct characteristic peaks at 280 and 450 nm, indicating successful reaction between PDA and DOX. The peak at 280 nm is attributed to PDA, while the peak at 450 nm is attributed to DOX [11]. We also measured the absorption peaks of DOX at different concentrations and fitted the corresponding regression curves for subsequent drug release calculations (Fig. 1F). As depicted in Fig. 1G, at pH 4.5, the DOX release rate reached 60% after 50 h. However, at pH 7.2, the DOX release efficiency was less than 20%. This can be attributed to the Schiff base bond between DOX and PDA, which breaks under acidic conditions, leading to increased DOX release. Characterization of RGD@PDA-DOX. A SEM image of RGD@PDA-DOX; B Zeta potential distributions of different NPs; C Particle size distribution of RGD@PDA-DOX; D The infrared spectrum of PDA, PDA-DOX, RGD@PDA-DOX; E UV spectra of DOX and PDA-DOX; F UV absorption standard curve of DOX; G Release rate of DOX under different pH conditions Table 1Particle size and zeta potential of DOX-PEG polymersFormulationParticle size (nm)PDIZeta potential (mV)PDA92±4.10.2222.8 ± 3.4PDA-DOX94±4.30.1834.6±4.2RGD@PDA-DOX102 ± 6.80.1528.5 ±3.8 Particle size and zeta potential of DOX-PEG polymers Photothermal conversion efficiency of RGD@PDA-DOX The photothermal conversion efficiency of RGD@PDA-DOX at different concentrations was further examined. As shown in Fig. 2A, with increasing concentration, the temperature of the solution rose faster. When the concentration of RGD@PDA-DOX was 200 µg/mL, the temperature of the solution reached 70 °C within 5 min. This indicates that RGD@PDA-DOX exhibits excellent photothermal conversion efficiency. Additionally, we simulated the photothermal conversion efficiency of RGD@PDA-DOX in a 35 mm petri dish. As shown in Fig. 2B, RGD@PDA-DOX could raise the temperature of the petri dish to 45 °C within 5 min, which is sufficient to kill cells in a short period. Photothermal conversion efficiency of RGD@PDA-DOX. A Heating curves of RGD@PDA-DOX at different concentrations; B RGD@PDA-DOX can rapidly increase the temperature of the culture dish within 5 min In vitro anti-tumor effect of RGD@PDA-DOX Due to the modification of RGD peptide, RGD@PDA-DOX can target tumor cells. As shown in Fig. 3A and B, after co-culturing KTC-1 cells with RGD@PDA-DOX for 4 h, endocytosis of RGD@PDA-DOX was observed, and the number of internalized particles increased over time. The synergistic effect of photothermal and chemotherapeutic actions of RGD@PDA-DOX on KTC-1 cells was further characterized. As shown in Figs. 3C and D, compared to the control group, both DOX and PDA NPs could inhibit tumor cell proliferation. After 48 h of DOX treatment, cell viability decreased to 30%. When PDA NPs were administered and irradiated with 808 nm light, cell viability decreased to 25% after 48 h. However, under the synergistic effect of both, cell viability significantly decreased to approximately 9% after 48 h. In vitro anti-tumor effect of RGD@PDA-DOX. A In vitro cellular internalization process of RGD@PDA-DOX, Scale bar 50 μm; B Fluorescence intensity during the internalization process of RGD@PDA-DOX; C Live/dead staining images of KTC-1 cells co-cultured with different groups of materials for 24 h, Scale bar 100 μm; D Cell viability of KTC-1 cells co-cultured with different groups of materials for 24 and 48 h. ***p < 0.05 In vivo toxicity of RGD@PDA-DOX Good biocompatibility is essential for material performance. Further observation of the slices revealed that in the DOX group, the mouse heart tissue was severely damaged, with unevenly distributed and varied depths of blue-stained nuclei, even leading to nuclear loss. The cytoplasm boundaries were indistinct, and cell morphology could not be observed. In contrast, the heart tissue staining slices of the NP-treated group were more intact and clear than the DOX group. In the liver slices, only a small amount of lymphocyte infiltration was observed, with the occasional presence of binucleated cells. The NP group exhibited slightly more binucleated and multinucleated cells than the control group, accompanied by mild inflammatory changes in hepatocytes, but these changes were not significant. These results indicate that RGD@PDA-DOX has minimal biological toxicity. Additionally, the body weights of mice in all groups increased slightly (Fig. 4A and B). In vivo toxicity of RGD@PDA-DOX. A Histopathological examination of heart, liver, lung and liver kidney tissues by H&E staining after treatment with different therapeutic groups; B Changes in body weight of mice in different groups In vivo anti-tumor effect of RGD@PDA-DOX Nude mice carrying thyroid tumors were treated with RGD@PDA-DOX + Laser. As shown in Fig. 5A, fluorescent signals were observed in the tumor after 6 h and remained strong throughout the experiment. After completion of the in vivo targeting experiment, all mice were sacrificed and dissected, and five organs (heart, liver, spleen, lung, kidney) and tumor tissue were collected. The fluorescent signals in each tissue were detected under the same excitation light. As shown in Fig. 5B and C, the fluorescence intensity in the tumor site was significantly higher than that in other visceral organs, and a lower fluorescence signal was observed in the liver, which is related to the nature of RGD@PDA-DOX itself. Moreover, we further analyzed the in vivo tumor growth curves and weights. After the treatment was completed, the solid tumors from the mice in each group are shown in Fig. 5D. Among them, the tumor mass of the RGD@PDA-DOX group was the lowest (Fig. 5E). Additionally, the in vivo tumor growth curves further demonstrated the excellent anti-tumor efficacy of RGD@PDA-DOX (Fig. 5F). In vivo anti-tumor effect of RGD@PDA-DOX. A Tumor targeting of RGD@PDA-DOX; B Fluorescence images of hearts, livers, spleens, lungs, kidneys, and tumor sites in mice; C Quantitative comparison of fluorescence intensity in mouse visceral organs; D Images of mouse treatment process and dissected tumor; E Tumor volume growth curves; F Tumor weights of mice after dissection. ***p < 0.05 Discussion Thyroid tumors, including benign and malignant types, are masses formed by abnormal cell proliferation within the thyroid tissue. For those thyroid tumors that are unresectable or insensitive to radiation therapy, PTT may emerge as an alternative treatment modality [12]. In the photothermal treatment of thyroid tumors, PTAs, such as PDA nanoparticles, are often employed. These nanoparticles can be guided to the tumor region through intravenous injection or other routes [13]. PDA is a nanodrug delivery platform with strong adhesion, excellent photothermal conversion, and good biocompatibility [14]. Its ability to promote molecular biological properties and enhance bioavailability allows PDA to be delivered together with chemotherapeutic drugs to enhance treatment effects. Simultaneously, PTT based on PDA has a synergistic effect, which is conducive to enhancing tumor treatment, especially in multimodal therapies such as the combination of photodynamic therapy (PDT) and PTT, which can convert molecular oxygen (O2) into cytotoxic reactive oxygen species (ROS) to destroy tumor cells [15]. However, differences in physicochemical properties between drugs lead to inconsistent in vivo metabolism, and nano-drug carriers solve this problem through co-encapsulation and targeted delivery technology. However, current nano-encapsulation techniques face challenges such as low encapsulation efficiency, poor encapsulation rate, and complex preparation. This study proposes a novel nano-carrier self-assembly technology that utilizes the interactions between drug molecules to construct multiple agents onto the same nanoscale particle, achieving tumor-targeted delivery. This technology overcomes the limitations of traditional nano-encapsulation processes by relying on the structural characteristics of polymers to induce polymer self-assembly. It has the advantages of one-step completion, high molecular concentration, large-scale preparation, and strong universality [16]. Inspired by natural melanin and mussel adhesive proteins, a biopolymer similar to natural melanin, PDA, has been extensively studied in surface modification, PTT, and bioimaging [17]. As an important biological macromolecule, PDA is widely present in the skin and hair of humans and animals, playing a central regulatory role in various physiological activities [18]. It possesses excellent biocompatibility, high pH sensitivity, and superior physiological stability. Additionally, PDA exhibits broad light absorption properties, making it an advantageous endogenous nanoplatform for tumor PAI and PTT. A study proposed a PDA-coated nucleic acid nanogel as a therapeutic complex (PP-NG) for siRNA-mediated low-temperature PTT. siRNAs targeting heat shock protein 70 (Hsp70) serve as crosslinkers, guiding the assembly of DNA-grafted polycaprolactone (DNA-g-PCL) into nanogel particles through nucleic acid hybridization. Finally, a thin layer of PDA is applied to the nanogel, not only protecting it from enzymatic degradation but also imparting excellent photothermal conversion efficiency. After surface PEGylation, this triple-shielded siRNA delivery complex exhibits effective tumor ablation capabilities [19]. In our experiments, PDA and DOX were interconnected via dynamic Schiff base reactions. On one hand, PDA serves as a photothermal material, killing tumor cells and inhibiting tumor growth within 5 min of laser irradiation. On the other hand, PDA functions as a drug carrier, releasing drugs at the tumor site, achieving a synergistic effect of photothermal therapy and drug therapy. Therefore, in our work, we have conjugated DOX with PDA through dynamic Schiff base reactions. On one hand, PDA-DOX can reduce the initial release of DOX through sustained release; on the other hand, it can respond to the tumor microenvironment, minimizing damage to other body parts[20]. Acknowledgements Not applicable. Author contributions D. Y. played a pivotal role in the conceptualization of the study and Z. L. contributed to the validation of the experimental results and X. X. was instrumental in developing the software used for data analysis and managing the data curation process and W. L. supervised the overall research. All authors reviewed the manuscript. Funding This study has received no funding support. Data availability Data is provided within the manuscript or supplementary information files. Declarations Ethics approval and consent to participate The animal study was conducted in accordance with the ethical standards and guidelines set forth by the Ethics Committee of The Experimental Animal Welfare Ethics Committee of Nanjing Medical University. The study protocol was reviewed and approved by the Ethics Committee, with the permit number: 2021031085. All procedures performed in this study involving animals were in compliance with the ARRIVE guidelines and the guidelines of the National Institutes of Health for the care and use of laboratory animals. The maximal tumor size permitted by our institutional ethics committee guidelines is 2 cm in diameter, or any tumor burden that does not cause significant discomfort, impaired mobility, or affect the well-being of the animal. We confirm that the maximal tumor size/burden as outlined by our ethics committee was not exceeded at any point during the study. In all cases, animals were closely monitored, and any discomfort or significant tumor growth was addressed promptly. In instances where tumors approached the size limit, animals were euthanized following the approved humane endpoints to avoid exceeding the permitted tumor burden. Consent for publication All authors reviewed this manuscript and agreed for publication. Competing interests The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data is provided within the manuscript or supplementary information files.